Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pharming presented positive Phase II topline data for leniolisib in genetic primary immunodeficiencies with immune dysregulation at ESID 2026. Study showed clinical improvements across key signs of immune dysregulation, supporting use beyond APDS; treatment was generally well tolerated. All participants who finished th
Pharming reported Phase II topline data for leniolisib in genetically identifiable PIDs with immune dysregulation, including reductions in spleen volume and trends in pulmonary function. Separate CVID Phase II topline data are expected in November.
The company presented initial high-level results for leniolisib in genetic primary immunodeficiencies with immune dysregulation at ESID 2026.
Pharming said it posted positive topline Phase II data for leniolisib in genetically defined PIDs with immune dysregulation, citing a mean 26.4% spleen volume reduction and no new safety signals. Additional data is planned for ESID 2026, and CVID topline is expected in Q4 2026.